Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30977156 | 1.00 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL4455756 | 0.91 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL4451947 | 0.88 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL4454819 | 0.86 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL4454316 | 0.86 | AKR1B1 (0.75) | AKR1B1 | |
| SCHEMBL4456376 | 0.85 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL4451833 | 0.85 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL6645036 | 0.84 | AKR1B1 (0.71) | AKR1B1 | |
| SCHEMBL4452391 | 0.83 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL4455112 | 0.83 | AKR1B1 (1.00) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029667-A1 | Spray dried formulation | BEND RESEARCH INC. | 2010-02-04 | — | — | US | claimed |
| EP-2101741-A2 | SOLID DISPERSION COMPRISING A POORLY WATER SOLUBLE DRUG | BEND RESEARCH, INC. (US) | 2009-09-23 | — | — | EP | claimed |
| WO-2008047201-A2 | SOLID DISPERSION COMPRISING A POORLY WATER SOLUBLE DRUG | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | claimed |
| US-6849629-B2 | Heteroaromatic substituted sulfonyl or sulfoxide or thio-pyridazinone derivatives, useful for treating diabetic complications and cardiovascular disorders | PFIZER, INC. (US) | 2005-02-01 | — | — | US | claimed |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | MYLARI BANAVARA L (US) | 2005-01-06 | — | — | US | claimed |
| EP-1373259-B1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | claimed |
| EP-1373259-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | claimed |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2003-08-28 | — | — | US | claimed |
| US-20030114357-A1 | Antidiabetic agents | FRYBURG DAVID A (US) | 2003-06-19 | — | — | US | claimed |
| US-6579879-B2 | Pyridazinone aldose reductase inhibitors | PFIZER INC | 2003-06-17 | — | — | US | claimed |
| WO-2002079198-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-10-10 | — | — | WO | claimed |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2002-10-03 | — | — | US | claimed |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-02-17 | — | — | US | disclosed |
| US-12551467-B2 | Compositions and methods of modulating S-nitrosylation | CASE WESTERN RESERVE UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3226859-B1 | AKR1A1 INHIBITORS FOR USE IN LOWERING CHOLESTEROL AND MODULATE S-NITROSYLATION | UNIV CASE WESTERN RESERVE (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4470609-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2024-12-04 | — | — | EP | disclosed |
| EP-1298223-A2 | Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene | Pfizer Products Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002087584-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002079198-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | AKR1B1 1078/4885 |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, ALDOA, AKR1B1 | AKR1B1 3/4885 |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, AKR1B1, AKR1D1 | AKR1B1 2/4885 |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | ALDOA, AKR1B1, ALDH2 | AKR1B1 2/4885 |
| US-20100029667-A1 | Spray dried formulation | PRKG1, PDE7A, PDE10A | AKR1B1 2677/4885 |
| US-12551467-B2 | Compositions and methods of modulating S-nitrosylation | AKR1A1, AKR1B1, AKR1D1 | AKR1B1 2/4885 |
| US-20030114357-A1 | Antidiabetic agents | AKR1B1, AKR1C2, AKR1C1 | AKR1B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.